5 results
* to describe the safety profile for qW, q2W and q3W regimens. * to determine the Maximum Tolerated Dose (MTD), if achieved (all regimens)* to describe the pharmacokinetics (PK) of single-agent RO6895882. Substudy BP28920/IMGThe study is designed to…
1) To identify new predictors of ST, especially 'late' and 'very late ST', 'drug eluting ST' and 'bio-absorbable scaffold thrombosis'.2) To observe clinical outcome after an episode of ST
Study BP29541 is a first in-human, open-label, multicenter, dose-escalation Phase I clinical study of single-agent RO6958688. The study will be conducted in two parts. Part I of the study is single ascending dose in single patient cohorts to…
The main objective of this pilot study is to evaluate the effect of motion mitigation with BiPAP or CPAP on tumor motion during the course of radiotherapy in patients with intra-thoracic tumors.
The primary objective of the study is to evaluate the efficacy of obinutuzumab(GA101) plus venetoclax (GVe) versus standard chemoimmunotherapy (BR/FCR)[concerning MRD negativity measured by flow cytometry in peripheral blood (PB)at month 15] and…